Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Potent Anti-Myeloma Activity of the TOPK inhibitor OTS514 in Pre-Clinical Models

ABSTRACT: Potent Anti-Myeloma Activity of the TOPK inhibitor OTS514 in Pre-Clinical Models

PROVIDER: PRJNA526885 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Pre-clinical models of genetically heterogeneous multiple myeloma reveal immune evasion mechanisms and predict clinical immunotherapy outcomes

Project description:The historical lack of pre-clinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers advancing therapeutic discoveries. To circumvent this limitation, we have generated fifteen genetically diverse models that developed bone marrow tumors fulfilling MM pathogenesis. Transcriptomic analysis of tumor plasma cells revealed that MYC activation regulates time to progression. Bone marrow cell composition analysis classified myeloma tumors into immune-cold and inflamed categories, which condition immune checkpoint blockade responses in mouse multiple myeloma models.

2023-03-17 | GSE205644 | GEO

Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.

Project description:Multiple myeloma (MM) continues to be considered incurable, necessitating new drug discovery. The mitotic kinase T-LAK cell-originated protein kinase/PDZ-binding kinase (TOPK/PBK) is associated with proliferation of tumor cells, maintenance of cancer stem cells, and poor patient prognosis in many cancers. In this report, we demonstrate potent anti-myeloma effects of the TOPK inhibitor OTS514 for the first time. OTS514 induces cell cycle arrest and apoptosis at nanomolar concentrations in a series of human myeloma cell lines (HMCL) and prevents outgrowth of a putative CD138+ stem cell population from MM patient-derived peripheral blood mononuclear cells. In bone marrow cells from MM patients, OTS514 treatment exhibited preferential killing of the malignant CD138+ plasma cells compared with the CD138- compartment. In an aggressive mouse xenograft model, OTS964 given orally at 100 mg/kg 5 days per week was well tolerated and reduced tumor size by 48%-81% compared to control depending on the initial graft size. FOXO3 and its transcriptional targets CDKN1A (p21) and CDKN1B (p27) were elevated and apoptosis was induced with OTS514 treatment of HMCLs. TOPK inhibition also induced loss of FOXM1 and disrupted AKT, p38 MAPK, and NF-κB signaling. The effects of OTS514 were independent of p53 mutation or deletion status. Combination treatment of HMCLs with OTS514 and lenalidomide produced synergistic effects, providing a rationale for the evaluation of TOPK inhibition in existing myeloma treatment regimens.

| S-EPMC6943155 | biostudies-literature

Potent Anti-Myeloma Activity of the TOPK inhibitor OTS514 in Pre-Clinical Models

Project description:Evaluation of gene expression upon treatment with OTS514 in combination with existing thereapeutics in H929 cells

2019-11-12 | GSE128251 | GEO

Pre-clinical models of genetically heterogeneous multiple myeloma reveal immune evasion mechanisms and predict clinical immunotherapy outcomes

Project description:Pre-clinical models of genetically heterogeneous multiple myeloma reveal immune evasion mechanisms and predict clinical immunotherapy outcomes

| PRJNA846769 | ENA

Pre-clinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Project description:Pre-clinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

| PRJNA912227 | ENA

Murine models of multiple myeloma: WGS

Project description:Murine models of multiple myeloma: WGS

| PRJEB18443 | ENA

Evaluating pre-clinical models for studying NASH driven HCC.

Project description:Evaluating pre-clinical models for studying NASH driven HCC.

| PRJNA474086 | ENA

Murine models of multiple myeloma: WGS

Project description:Characterization of genomic landscape of the 5T murine models for multiple myeloma, by whole-genome sequencing

2018-10-09 | E-MTAB-5302 | biostudies-arrayexpress

Pre-clinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Project description:Multiple myeloma (MM) is a neoplasia of bone marrow (BM) plasma cells that remains largely incurable with current treatment. Advancing therapeutic discoveries has been hampered by the lack of genetically heterogeneous models of MM. To circumvent this limitation, we engineered fifteen mouse models carrying combinations of eight MM genetic drivers, which fulfilled the pathogenesis of human disease including progression from premalignant states under immune surveillance. Integrative analyses of ⁓500 mice and ⁓1,000 patients revealed a MAPK-MYC genetic pathway that regulates time to progression and immune escape mechanisms across genetically heterogeneous tumors. During progression, MYC-dependent and independent remodeling of the BM microenvironment divided MM into immune categories with predominance of selected T-cell subpopulations, which dictated immunotherapy responses. Experimental targeting of the cytotoxic or immunosuppressive T-cell states observed in refractory MM patients enhanced immunotherapy effectiveness. Our resource enabled characterization of MM cell-intrinsic and immunological traits at unprecedented levels, which will accelerate the translation of personalized immunotherapy.

2023-01-31 | GSE220997 | GEO

Development Of Pre-Clinical Murine Models For Fibrolamellar Hepatocellular Carcinoma

Project description:Development Of Pre-Clinical Murine Models For Fibrolamellar Hepatocellular Carcinoma

| PRJNA1048524 | ENA